Pulmonary embolism is the blockage of the blood vessels in the lungs usually due to blood clots from the veins, especially the veins in the legs and pelvis.
Dyspnea, chest pain, syncope or tachypnea (respiratory rate of ≥20/min) occur in most cases of pulmonary embolism.
Pleuritic chest pain with or without dyspnea is one of the most frequent presentations of this disease.
Syncope or shock are the hallmark signs of central pulmonary embolism and usually result in severe hemodynamic repercussions.
Signs of hemodynamic compromise and reduced heart flow are also usually present.
Patients with chronic thromboembolic pulmonary hypertension (CTEPH) may experience improvements in exercise capacity and other outcomes when treated with a continuous, subcutaneous, high dose of treprostinil, according to the phase III CTREPH* trial.
Transfusion of red blood cells (RBC) in patients hospitalized with acute pulmonary embolism (PE) is uncommon and may increase the risk of short- and long-term mortality, independent of haemoglobin (Hb) level on admission, suggests a study.